Horm Metab Res 2019; 51(10): 634-638
DOI: 10.1055/a-0991-0231
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Definition of the Response to Initial Therapy with Radioiodine in Patients with Differentiated Thyroid Carcinoma: Basal or Stimulated Thyroglobulin?

Pedro Weslley Rosario
1   Santa Casa de Belo Horizonte, Minas Gerais, Brazil
Gabriela Franco Mourão
1   Santa Casa de Belo Horizonte, Minas Gerais, Brazil
Maria Regina Calsolari
1   Santa Casa de Belo Horizonte, Minas Gerais, Brazil
› Author Affiliations
Further Information

Publication History

received 25 June 2019

accepted 01 August 2019

Publication Date:
02 October 2019 (online)


Basal thyroglobulin (b-Tg) measured with second-generation assay or stimulated Tg (s-Tg) can be used to define the response to therapy of differentiated thyroid carcinoma. However, they do not always define the same category and guidelines do not establish “if” or “when” s-Tg needs to be obtained. We studied 304 patients without clinically apparent disease or disease detected by neck ultrasonography and without anti-Tg antibodies 9–12 months after therapy. Based on b-Tg, 196 patients had an excellent response and 108 had an indeterminate response. Based on s-Tg, a change in category occurred in 10.2% of the patients with an initial excellent response (all to indeterminate response) and in half the patients with an initial indeterminate response (44.4% to excellent response and 5.5% to biochemical incomplete response). One case of recurrence was observed among patients with an initial excellent response but whose response changed to indeterminate after s-Tg, while no disease was detected among those who remained in the initial category; however, this difference was not significant. In patients with an initial indeterminate response, no recurrence was detected among those whose response changed to excellent after s-Tg, while 11.1 and 33.3% of those who remained in the initial category or whose response changed to biochemical incomplete, respectively, had structural disease. This study suggest that, in low- or intermediate-risk patients, s-Tg better defines the response to therapy with 131I when it is classified as indeterminate based on b-Tg using second-generation assay. However, s-Tg is not necessary when b-Tg defines the response as excellent.

  • References

  • 1 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26: 1-133
  • 2 Pacini F, Basolo F, Bellantone R. et al. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: Joint statements of six Italian societies. J Endocrinol Invest 2018; 41: 849-876
  • 3 Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 2014; 43: 401-421
  • 4 Zerdoud S, Giraudet AL, Leboulleux S. et al. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 Guidelines of the French Societies of nuclear medicine, endocrinology, pathology, biology, endocrine surgery and head and neck surgery. Ann Endocrinol (Paris) 2017; 78: 162-175
  • 5 Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4<1 ng/ml determined by traditional assays?. Clin Endocrinol (Oxf) 2008; 68: 338-342
  • 6 Rosario PW, Siman TL, Calsolari MR. Day 3 thyroglobulin ≤ 1 ng/ml after recombinant human TSH just prior to radioactive iodine is predictive of low risk for persistent/recurrent disease in patients with papillary thyroid carcinoma. Endocrine 2015; 49: 170-174
  • 7 Rosario PW, de Faria S, Bicalho L. et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 2005; 24: 1385-1389
  • 8 Rosario PW, Tavares WC, Borges MA. et al. Ultrasonographic differentiation of cervical lymph nodes in patients with papillary thyroid carcinoma after thyroidectomy and radioiodine ablation: A prospective study. Endocr Pract 2014; 20: 293-298
  • 9 Delbeke D, Coleman RE, Guiberteau MJ. et al. Procedure Guideline for SPECT/CT Imaging 1.0. J Nucl Med 2006; 47: 1227-1234
  • 10 Boellaard R, O'Doherty MJ, Weber WA. et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010. 37 181-200
  • 11 Rosario PW, Mourão GF, Siman TL. et al. Serum thyroglobulin measured with a second-generation assay in patients undergoing total thyroidectomy without radioiodine remnant ablation: A prospective study. Thyroid 2015; 25: 769-775
  • 12 Beltsevich DG, Vanushko VE, Rumiantsev PO. et al. 2017 Russian clinical practice guidelines for differentiated thyroid cancer diagnosis and treatment. Endocr Surg 2017; 11: 6-27
  • 13 Jarząb B, Dedecjus M, Słowińska-Klencka D. et al. Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update Endokrynol Pol 2018; 69: 34-74
  • 14 Tuttle RM, Tala H, Shah J. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the New American Thyroid Association staging system. Thyroid 2010; 20: 1341-1349
  • 15 Kim TH, Ki CS, Kim HS. et al. Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with tert promoter mutations. J Clin Endocrinol Metab 2017; 102: 1757-1764
  • 16 van Velsen EFS, Stegenga M, van Kemenade FJ. et al. Evaluating the 2015 American Thyroid Association risk stratification system in high risk papillary and follicular thyroid cancer patients. Thyroid 2019; DOI: 10.1089/thy.2019.0053.
  • 17 Brassard M, Borget I, Edet-Sanson A. et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: A prospective study on 715 patients. J Clin Endocrinol Metab 2011; 96: 1352-1359
  • 18 Chindris AM, Diehl NN, Crook JE. et al. Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: Results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab 2012; 97: 2714-2723
  • 19 Malandrino P, Latina A, Marescalco S. et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 2011; 96: 1703-1709
  • 20 Castagna MG, Tala Jury HP, Cipri C. et al. The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest 2011; 34: e219-223
  • 21 Hu HY, Liang J, Zhang T. et al. Suppressed thyroglobulin performs better than stimulated thyroglobulin in defining an excellent response in patients with differentiated thyroid cancer. Nucl Med Commun 2018; 39: 247-251
  • 22 Spencer C, Fatemi S, Singer P. et al. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010; 20: 587-595
  • 23 Rosário PW, Fagundes TA, Rezende LL. et al. Assessing hypothyroidism in the preparation of patients with thyroid cancer: Cardiovascular risk, renal function, drug metabolism, persistence of elevated thyroid-stimulating hormone, and absence from work. Endocrinologist 2006; 16: 25-29
  • 24 Trimboli P, Imperiali M, Piccardo A. et al. Multicentre clinical evaluation of the new highly sensitive Elecsys® thyroglobulin II assay in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2018; 88: 295-302
  • 25 Malandrino P, Tumino D, Russo M. et al. Surveillance of patients with differentiated thyroid cancer and indeterminate response: A longitudinal study on basal thyroglobulin trend. J Endocrinol Invest 2019; DOI: 10.1007/s40618-019-01044-3.
  • 26 Rosario PW, Furtado M, de S, Mineiro Filho AF. et al. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence. Thyroid 2012; 22: 1165-1169
  • 27 Rosario PW, Mourão GF, dos Santos JB. et al. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?. Thyroid 2014; 24: 533-536